General Cardiology

Featured Content

Volatile Anesthetics Do Not Reduce Deaths in Elective CABG

No significant difference seen for patients undergoing CABG with volatile anesthesia.

Latest News

Cardiovascular Mortality Burden High Among Young Adults With ESRD

Cardiovascular causes accounted for nearly 40% of deaths among study patients age 22 to 29 years at onset of treatment for kidney failure.

AAP: Nasal Spray Vaccine Against Flu Acceptable in 2019 to 2020

Based on current data, AAP Board of Directors says either injection or nasal spray vaccination is okay.

Regulatory Approval Filed for Semaglutide Seeking CV Risk Reduction Indication

Novo Nordisk has submitted 2 New Drug Applications (NDAs) for oral semaglutide as well as a supplemental NDA (sNDA) for subcutaneous (SC) semaglutide (glucagon-like peptide-1; Ozempic).

No Difference Between Antiplatelet Agents vs Anticoagulants in Recurrent Stroke Risk After Cervical Dissection

Researchers found a low rate of recurrent stroke after carotid and vertebral dissection and no difference between antiplatelet agents and anticoagulants.

Adjunctive Antibacterial Envelope Use Lowers Major CIED Infection Incidence

Incidence of major cardiac implantable electronic device infections significantly lower with envelope.

MitraClip Device Approved for Patients With Secondary Mitral Regurgitation

Data show 47 percent reduction in risk for rehospitalization for HF symptoms with device implantation

High-Risk HPV May Be Associated With Cardiovascular Disease in Women

High-risk human papillomavirus infection may be associated with the risk for cardiovascular disease in Korean women.

Linagliptin Non-Inferior to Glimepiride in Long-Term CV Outcome Study

The CAROLINA trial met its primary endpoint, demonstrating no increased CV risk with linagliptin, a DPP-4 inhibitor, when compared with glimepiride, a sulfonylurea, in patients with type 2 diabetes and CV risk.

Hormone Therapy May Affect Cardiovascular Profiles in Transgender Persons

Investigators evaluated whether treatment with one year of oral or transdermal administration of estrogen plus cyproterone and transdermal or intramuscular application of testosterone caused changes in serum lipids and blood pressure.

First Trimester Maternal Ondansetron Use Not Linked With Cardiac Malformation Risk

Maternal use of ondansetron during the first trimester of pregnancy was not found to be associated with cardiac or congenital malformation in offspring but may be linked to oral cleft development.